MVT’s mission is to develop the next generation of contrast agents for diagnostic ultrasound and advance the field of ultrasound for diagnosis and treatment of disease.
The founders of MVT developed the world’s #1 selling ultrasound contrast agent, Definity®.
MVT has developed a new, patented formulation, MVT-100 for use as ultrasound contrast agent. Compared to Definity®, MVT-100 may afford potential for room temperature storage, while
Definity® requires refrigerated storage. MVT-100 has a neutral surface chemistry, potentially serving as a platform for development of agents for molecular imaging and image-guided
therapy. MVT has received formal guidance from the FDA that MVT-100 can be developed via the 505(b)(2) pathway. The Company has designed an accelerated development pathway to potentially lead to approval of MVT-100 for echocardiography.